ABION (A203400) Stock Overview
Operates as a pharmaceutical biotech Company in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A203400 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ABION Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,770.00 |
| 52 Week High | ₩7,277.78 |
| 52 Week Low | ₩1,911.11 |
| Beta | 1.04 |
| 1 Month Change | -1.44% |
| 3 Month Change | 32.02% |
| 1 Year Change | -5.22% |
| 3 Year Change | 2.05% |
| 5 Year Change | -22.09% |
| Change since IPO | 17.00% |
Recent News & Updates
Shareholder Returns
| A203400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 23.8% | 3.6% | 4.2% |
| 1Y | -5.2% | 45.5% | 71.0% |
Return vs Industry: A203400 underperformed the KR Biotechs industry which returned 45.5% over the past year.
Return vs Market: A203400 underperformed the KR Market which returned 71% over the past year.
Price Volatility
| A203400 volatility | |
|---|---|
| A203400 Average Weekly Movement | 17.2% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A203400's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A203400's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 38 | Young-Gi Shin | abionbio.com |
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters.
ABION Inc. Fundamentals Summary
| A203400 fundamental statistics | |
|---|---|
| Market cap | ₩181.07b |
| Earnings (TTM) | -₩28.06b |
| Revenue (TTM) | ₩1.03b |
Is A203400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A203400 income statement (TTM) | |
|---|---|
| Revenue | ₩1.03b |
| Cost of Revenue | ₩724.42m |
| Gross Profit | ₩306.92m |
| Other Expenses | ₩28.37b |
| Earnings | -₩28.06b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -529.28 |
| Gross Margin | 29.76% |
| Net Profit Margin | -2,721.01% |
| Debt/Equity Ratio | 218.5% |
How did A203400 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 17:36 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABION Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.